Stock Analysis of Biofrontera Inc. WT (BFRIW) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BFRIW
Close 0.065
Change 0 / 0 %
Volume 18941.00
Vol Change 18341.00 / 3056.83 %
IndustryDrug Manufacturers-Specialty & Generic
SectorHealthcare
AIO Strength Index
Technical StrengthBullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Biofrontera Inc. WT
PE (TTM)

-5.01

Very Poor
Price / Book

20.75

Very Poor
Price / Sales

3.49

Very Poor
Piotroski F Score

4.0

Indecisive
Market Cap

0

Enterprise Value

0

ROA (TTM)

-69.77

Very Poor
ROE (TTM)

-474.36

Very Poor
Net Margin (TTM)

-69.57

Very Poor
Revenue

17.25 %

33619.00 K
Net Profit

4031.56 %

-26442.00 K
Debt to Equity

0.959

Good
Altman Z Score

-6.59

Very Poor
Quick Ratio

0.673

Not Good
Cash Ratio

0.074

Poor


Highs/Lows of Biofrontera Inc. WT
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.06 8.33 % 1.54 % 0.06590.059515-May-2409-May-24
Two Week0.06 8.33 % 3.42 % 0.06590.059515-May-2409-May-24
One Month0.0454 43.17 % 5.60 % 0.06590.034915-May-2418-Apr-24
Three Month0.0105 519.05 % 5.95 % 0.07450.010723-Feb-2416-Feb-24
Six Months0.029 124.14 % 17.48 % 0.07450.00523-Feb-2419-Dec-23
One year0.2163 69.95 % 27.52 % 0.30050.00503-Jul-2319-Dec-23
Two year1.13 94.25 % 29.70 % 1.18990.00524-May-2219-Dec-23


Technical View of Biofrontera Inc. WT
RSI

56.61

Neutral
MACD

0.0054

Bullish
ADX

10.71

Neutral
Super Trend

0.0460

Mild Bullish
Williams %R

-2.90

Mild Bearish
CCI

94.24

Strong Bearish


EMA 5

0.064

Bullish
EMA 15

0.058

Strong Bullish
EMA 50

0.0477

Strong Bullish
EMA 100

0.054

Whipsaw
SMA 100

0.0325

Strong Bullish
SMA 200

0.082

Mild Bearish
SMA 5 / 20

0.064 / 0.053

Strong Bullish
SMA 15 / 50

0.056 / 0.0455

Strong Bullish
SMA 50 / 200

0.0455 / 0.082

Mild Bearish




Charts of Biofrontera Inc. WT


Returns of Biofrontera Inc. WT with Peers
Period / StockBFRIWNEPTACORQSAMUTRS
1 Week8.33%-57.89%-60.65%2.60%0%
1 Mth43.17%-57.89%-94.49%12.16%-99.82%
3 Mth519.05%-61.98%-95.96%55.14%-99.88%
6mth124.14%-96.87%-93.85%59.62%-99.97%
1 Year-69.95%-99.09%-93.99%38.91%-99.98%
2 Year-94.25%-99.96%-98.01%43.10%-100.00%
5 Years--100.00%-99.96%2113.33%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Biofrontera Inc. WT with Peers
Ratio / StockBFRIWNEPTACORQSAMUTRS
PE-5.01-0.0112-0.0017-5.01-0.0232
P/B20.75-0.0205-0.0346-49.990.051
ROA-69.77-416.28-170.31-576.91-66.79
ROE-474.36000-217.71
Debt To Equity0.959-1.95-0.01010.04600
Revenue33619.00 K
17.25 % 		52615.34 B
107824570 % 		111118 K
6.28 % 		0
% 		51693.00 K
2.78 %
Net Income-26442.00 K
4031.56 % 		-170880.45 B
241130345 % 		-15951.00 K
75.80 % 		-5085.07 K
16.29 % 		-33450.00 K
1.94 %


Technicals of Biofrontera Inc. WT with Peers
Technical / StockBFRIWNEPTACORQSAMUTRS-
ADX10.7122.4139.1624.4335.70
CMF0.627-0.577-0.4380.4950.0444
MFI53.5579.480.92566.662.82
RSI56.6130.8617.0468.6930.41
MACD Abv SignalTrueFalseFalseFalseFalse
Price Above 50 MATrueFalseFalseTrueFalse-
Price Above 200 MAFalseFalseFalseTrueFalse-


About : Biofrontera Inc. Warrants

Address : 120 Presidential Way, Woburn, MA, United States, 01801
Tel : 781-245-1325
URL : https://www.biofrontera-us.com
Code : BFRIW, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 29_Oct_2021
Employee Count : 83

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)